MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms. Semin Oncol 2015 Dec;42(6):849-62
Date
11/29/2015Pubmed ID
26615130Pubmed Central ID
PMC4663016DOI
10.1053/j.seminoncol.2015.09.023Scopus ID
2-s2.0-84962305085 (requires institutional sign-in at Scopus site) 85 CitationsAbstract
Aberrant activation of the three-layered protein kinase cascade, Raf/MEK/ERK, is often detected in human cancer, which is mainly attributed to the oncogenic alterations of RAF, or its upstream activators RAS or cell surface receptor tyrosine kinases. Deregulated activity of the Raf/MEK/ERK pathway drives uncontrolled tumor cell proliferation and survival, thus providing a rational therapeutic target for the treatment of many cancers. While Raf, MEK1/2, and ERK1/2 are equally important targets for the design of therapeutic small molecular weight inhibitors, the effort to develop MEK1/2-specific inhibitors has been greatly successful. Particularly, MEK1/2 have been relatively advantageous for the design of highly selective adenosine triphosphate (ATP)-noncompetitive inhibitors. Indeed, a plethora of highly selective and potent MEK1/2 inhibitors are now available and many of those inhibitors have been evaluated for their therapeutic potential. Herein, we review different MEK1/2 inhibitors that have been studied for their inhibitory mechanisms and therapeutic potential in cancer. Some of the key structural features of MEK1/2 that are important for the efficacy of these inhibitors are also discussed. In addition, we discuss current challenges and future prospective in using these advanced MEK1/2 inhibitors for cancer therapy.
Author List
Wu PK, Park JIAuthor
Jong-In Park PhD Professor in the Biochemistry department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Drug Resistance, NeoplasmHumans
MAP Kinase Kinase 1
MAP Kinase Kinase 2
Molecular Targeted Therapy
Neoplasms
Protein Kinase Inhibitors
